AAS
SRPT icon

Avantax Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Avantax Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,375
Closed -$895K – 1312
2020
Q3 		$895K Buy
+6,375
New +$969K 0.01% 566

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Avantax Advisory Services's SRPT Position: Q4 2020 in Review

Avantax Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q4 2020, closing a stake of 6,375 shares — an estimated $895K sold.

Avantax Advisory Services first reported a position in SRPT in Q3 2020 and held it in 1 quarter. The position peaked at $895K in Q3 2020. 454 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

  • Avantax Advisory Services reported no remaining Sarepta Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Avantax Advisory Services sold 6,375 Sarepta Therapeutics shares in Q4 2020, an estimated $895K.
  • Avantax Advisory Services first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 1 quarter.
  • Avantax Advisory Services's Sarepta Therapeutics position peaked at $895K in Q3 2020.
  • 454 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on Avantax Advisory Services's 13F filing for Q4 2020, filed 22 Jan 2021.